TY - JOUR
T1 - Endometrial tumor immune response
T2 - Predictive biomarker of response to immunotherapy
AU - Mullen, Mary M.
AU - Mutch, David G.
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/4/15
Y1 - 2019/4/15
N2 - The tumor-specific immune response in endometrial cancer is variable within molecular subtypes. Thus, the tumor immune response offers a novel biomarker, separate from molecular subtypes, to predict which patients might respond to immunotherapy.
AB - The tumor-specific immune response in endometrial cancer is variable within molecular subtypes. Thus, the tumor immune response offers a novel biomarker, separate from molecular subtypes, to predict which patients might respond to immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85064742332&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-18-4122
DO - 10.1158/1078-0432.CCR-18-4122
M3 - Article
C2 - 30692101
AN - SCOPUS:85064742332
SN - 1078-0432
VL - 25
SP - 2366
EP - 2368
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 8
ER -